Requesting the President to transmit certain information to the House of Representatives relating to the proposed waiver of intellectual property commitments under the World Trade Organization Agreement on Trade- Related Aspects of Intellectual Property Rights.
This resolution requests that the President transmit certain information to the House of Representatives related to the proposed waiver of intellectual property commitments under the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (known as the TRIPS waiver). In particular, the resolution requests information demonstrating that (1) the TRIPS waiver will increase global supply and delivery of COVID-19 vaccines, (2) the waiver will accelerate the end of the COVID-19 pandemic, or (3) China will not obtain access to patents or other intellectual property related to COVID-19 vaccines even if expressly excluded from the waiver.
AsiaCardiovascular and respiratory healthChinaCongressional-executive branch relationsCongressional oversightEmergency medical services and trauma careFree trade and trade barriersHealth technology, devices, suppliesImmunology and vaccinationInfectious and parasitic diseasesIntellectual propertyPresidents and presidential powers, Vice PresidentsTrade agreements and negotiationsWorld health
Requesting the President to transmit certain information to the House of Representatives relating to the proposed waiver of intellectual property commitments under the World Trade Organization Agreement on Trade- Related Aspects of Intellectual Property Rights.
USA117th CongressHRES-1169| House
| Updated: 6/9/2022
This resolution requests that the President transmit certain information to the House of Representatives related to the proposed waiver of intellectual property commitments under the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (known as the TRIPS waiver). In particular, the resolution requests information demonstrating that (1) the TRIPS waiver will increase global supply and delivery of COVID-19 vaccines, (2) the waiver will accelerate the end of the COVID-19 pandemic, or (3) China will not obtain access to patents or other intellectual property related to COVID-19 vaccines even if expressly excluded from the waiver.
AsiaCardiovascular and respiratory healthChinaCongressional-executive branch relationsCongressional oversightEmergency medical services and trauma careFree trade and trade barriersHealth technology, devices, suppliesImmunology and vaccinationInfectious and parasitic diseasesIntellectual propertyPresidents and presidential powers, Vice PresidentsTrade agreements and negotiationsWorld health